Mayne Pharma is an ASX-listed specialty pharmaceutical company, selling products in Australia and internationally for birth control and menopause treatments. The proposed transaction is in line with its priority to deliver value to shareholders and provides significant benefits for their broader stakeholders.
The transaction was led by Partner and Head of Investment Funds Adam Laura, together with Corporate Advisory Partner Nirangjan Nagarajah, and with support from team members Tom Riley and Jordan Czelen.
Adam commented:
This transaction represents a key milestone for Mayne Pharma as it navigates the complexities of a dynamic industry. We are proud to have played a role in helping them achieve this strategic outcome.
